XERS vs. CTMX

Last updated Apr 1, 2026

Compare and contrast key facts about Xeris Biopharma Holdings, Inc. (XERS) and CytomX Therapeutics, Inc. (CTMX).

Performance

XERS vs. CTMX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Xeris Biopharma Holdings, Inc. (XERS) and CytomX Therapeutics, Inc. (CTMX). The values are adjusted to include any dividend payments, if applicable.

XERS vs. CTMX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018
XERS Xeris Biopharma Holdings, Inc.	-26.11%	131.56%	44.26%	76.69%	-54.61%	-40.45%	-30.21%	-58.53%	-15.92%
CTMX CytomX Therapeutics, Inc.	10.33%	313.59%	-33.55%	-3.13%	-63.05%	-33.89%	-21.18%	-44.97%	-39.24%

Fundamentals

Market Cap XERS : $1.04B CTMX : $799.88M
EPS XERS : $0.00 CTMX : -$0.11
PS Ratio XERS : 3.40 CTMX : 9.55
PB Ratio XERS : 76.30 CTMX : 8.08
Total Revenue (TTM) XERS : $291.85M CTMX : $76.20M
Gross Profit (TTM) XERS : $171.71M CTMX : $75.69M
EBITDA (TTM) XERS : $37.67M CTMX : -$19.39M

Returns By Period

In the year-to-date period, XERS achieves a -26.11% return, which is significantly lower than CTMX's 10.33% return.

XERS

• 1D: 3.57%
• 1M: -5.23%
• YTD: -26.11%
• 6M: -28.75%
• 1Y: 5.65%
• 3Y*: 52.67%
• 5Y*: 5.16%
• 10Y*: —

CTMX

• 1D: 6.58%
• 1M: -12.48%
• YTD: 10.33%
• 6M: 47.34%
• 1Y: 639.23%
• 3Y*: 46.01%
• 5Y*: -9.80%
• 10Y*: -9.91%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

XERS vs. CTMX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

XERS

XERS Risk / Return Rank: 44
XERS Sharpe Ratio Rank: 45
XERS Sortino Ratio Rank: 45
XERS Omega Ratio Rank: 45
XERS Calmar Ratio Rank: 43
XERS Martin Ratio Rank: 43

CTMX

CTMX Risk / Return Rank: 98
CTMX Sharpe Ratio Rank: 98
CTMX Sortino Ratio Rank: 98
CTMX Omega Ratio Rank: 97
CTMX Calmar Ratio Rank: 99
CTMX Martin Ratio Rank: 99

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

XERS vs. CTMX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Xeris Biopharma Holdings, Inc. (XERS) and CytomX Therapeutics, Inc. (CTMX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	XERS	CTMX	Difference
Sharpe ratio Return per unit of total volatility	0.09	3.81	-3.72
Sortino ratio Return per unit of downside risk	0.59	4.71	-4.11
Omega ratio Gain probability vs. loss probability	1.08	1.61	-0.53
Calmar ratio Return relative to maximum drawdown	0.08	15.76	-15.67
Martin ratio Return relative to average drawdown	0.18	36.65	-36.47
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

XERS vs. CTMX - Sharpe Ratio Comparison

The current XERS Sharpe Ratio is 0.09, which is lower than the CTMX Sharpe Ratio of 3.81. The chart below compares the historical Sharpe Ratios of XERS and CTMX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	XERS	CTMX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.09	3.81	-3.72
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.07	-0.07	+0.14
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	-0.09	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.19	-0.08	-0.10

Correlation

The correlation between XERS and CTMX is 0.30, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

XERS vs. CTMX - Dividend Comparison

Neither XERS nor CTMX has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

XERS vs. CTMX - Drawdown Comparison

The maximum XERS drawdown since its inception was -96.22%, roughly equal to the maximum CTMX drawdown of -98.74%. Use the drawdown chart below to compare losses from any high point for XERS and CTMX.

Drawdown Indicators

	XERS	CTMX	Difference
Max Drawdown Largest peak-to-trough decline	-96.22%	-98.74%	+2.52%
Max Drawdown (1Y) Largest decline over 1 year	-46.57%	-41.14%	-5.43%
Max Drawdown (5Y) Largest decline over 5 years	-78.59%	-95.65%	+17.06%
Max Drawdown (10Y) Largest decline over 10 years	—	-98.74%	—
Current Drawdown Current decline from peak	-78.70%	-86.27%	+7.57%
Average Drawdown Average peak-to-trough decline	-79.09%	-70.40%	-8.69%
Ulcer Index Depth and duration of drawdowns from previous peaks	21.96%	17.69%	+4.27%

Volatility

XERS vs. CTMX - Volatility Comparison

The current volatility for Xeris Biopharma Holdings, Inc. (XERS) is 14.68%, while CytomX Therapeutics, Inc. (CTMX) has a volatility of 53.47%. This indicates that XERS experiences smaller price fluctuations and is considered to be less risky than CTMX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	XERS	CTMX	Difference
Volatility (1M) Calculated over the trailing 1-month period	14.68%	53.47%	-38.79%
Volatility (6M) Calculated over the trailing 6-month period	43.12%	74.27%	-31.15%
Volatility (1Y) Calculated over the trailing 1-year period	61.69%	169.33%	-107.64%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	69.45%	142.15%	-72.70%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	79.84%	111.35%	-31.51%

Financials